CD80
白细胞清除术
单核细胞
CD86
细胞毒性T细胞
树突状细胞
外周血单个核细胞
CD40
生物
免疫学
分子生物学
抗原
化学
T细胞
免疫系统
细胞生物学
体外
生物化学
干细胞
川地34
作者
Vinod Pullarkat,Roy Lau,Sun Min Lee,James Bender,Jeffrey S. Weber
标识
DOI:10.1016/s0022-1759(02)00181-3
摘要
Conventional methods for generating monocyte-derived dendritic cells (DC) for clinical trials utilize the property of plastic adherence to select monocytes from leukapheresis samples. This method is labor-intensive and has the potential for contamination at various steps. We evaluated a large-scale monocyte enrichment procedure using a cell selector (Isolex 300i®) followed by culture in a sterile bag system (Stericell®) for generation of DC. DC generated in tissue culture flasks after monocyte selection by plastic adherence were compared to those generated in Stericell® bags after monocyte enrichment by negative selection with the Isolex® 300i. DC were matured with lipopolysaccharide and pulsed with a peptide derived from the melanoma antigen gp100. Peptide-pulsed DC cultured by the two techniques were evaluated for phenotype, viability, ability to induce allogeneic and peptide-specific autologous proliferative responses as well as peptide-specific cytotoxic T-cell responses. The mean monocyte yield from leukapheresis collections was 17±2.4%, which increased to 52±11% after Isolex® selection. The DC yield of plated mononuclear cells from flasks or bags was 2.7±0.96% and 4.84±2.65%, respectively. DC cultured by both methods expressed high levels of CD86, CD80, CD40, CD83, CD44, CD11c and CD58, and was comparable in their ability to induce allogeneic and peptide-specific autologous proliferative responses as well as gp100 peptide-specific cytotoxic T-cell responses. These results indicate that potent monocyte-derived DC can be generated in a closed culture bag system after monocyte enrichment by immunomagnetic negative selection. Due to the closed nature of the enrichment and culture systems, the potential for contamination is minimized. This protocol is well suited for culturing large numbers of DC for clinical immunotherapy trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI